Lamivudina shortage — IT supply status & alternatives

Lamivudina

—

In supply · Australia

Lamivudina Aurobindo Italia

In supply · 🇦🇺 Australia · short in🇮🇹 IT🇪🇸 ES

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Lamivudina
Brand names	Lamivudina Aurobindo Italia
Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇮🇹 IT

€55.31

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇮🇹 7 July 2026

medium reported

🇮🇹 15 Apr 2026

critical reported

🇮🇹 1 Apr 2026

medium reported

🇪🇸 27 Feb 2026

high reported

🇮🇹 11 Sept 2025

medium reported

🇮🇹 29 Sept 2023

Shortage resolved

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.